Table 1 Patient demographics and baseline characteristics
|  | Patients (N = 60) |
|---|---|
Mean age, years ± SD | 54.0 ± 10.3 |
Sex, n (%) | |
 Male | 55 (91.7) |
 Female | 5 (8.3) |
ECOG PS score, n (%) | |
 0 | 24 (40.0) |
  ≥ 1 | 36 (60.0) |
HBsAg, n (%) | |
 Positive | 51 (85.0) |
 Negative | 9 (15.0) |
Child-Pugh class, n (%) | |
 A | 58 (96.7) |
 B | 2 (3.3) |
α-Fetoprotein, n (%) | |
  < 400 ng/ml | 21 (35.0) |
  ≥ 400 ng/ml | 39 (65.0) |
BCLC stage, n (%) | |
 A | 2 (3.3) |
 B | 12 (20.0) |
 C | 46 (76.7) |
CNLC stage, n (%) | |
 Ib | 2 (3.3) |
 IIa | 2 (3.3) |
 IIb | 10 (16.7) |
 IIIa | 30 (50.0) |
 IIIb | 16 (26.7) |
Macrovascular invasion, n (%)a | |
 Portal vein | 28 (46.7) |
 Hepatic vein and/or vena cava | 5 (8.3) |
Extrahepatic metastases, n (%) | |
 Lung | 7 (11.7) |
 Lymph node | 6 (10.0) |
 Adrenal gland | 2 (3.3) |
 Intra-abdominal implantation | 2 (3.3) |